Medical Devices Ordinance
(MedDO)


Open article in different language:  DE  |  FR  |  IT
Art. 75 Principle

1 In­spec­tions un­der the aus­pices of mar­ket sur­veil­lance shall cov­er devices made avail­able on the mar­ket, con­form­ity as­sess­ment pro­ced­ures, device sur­veil­lance, device hand­ling and eco­nom­ic op­er­at­ors’ ful­fil­ment of their ob­lig­a­tions. They shall also cov­er devices made avail­able in con­tract­ing states by nat­ur­al or leg­al per­sons dom­i­ciled in Switzer­land, the con­form­ity as­sess­ment pro­ced­ures and sur­veil­lance activ­it­ies for such devices and the nat­ur­al or leg­al per­sons’ ful­fil­ment of their ob­lig­a­tions.

2 The mar­ket sur­veil­lance activ­it­ies un­der­taken by Swiss­med­ic and the Can­tons are gov­erned by Art­icle 66 TPA and Art­icles 93–95, 97 and 98 EU MDR115. Art­icles 97 para­graph 3 and 98 para­graphs 3 and 4 EU MDR are ex­cluded.116

3 The Can­tons shall draw up an­nu­al plans for their mar­ket sur­veil­lance activ­it­ies un­der para­graph 2. They shall provide Swiss­med­ic with an an­nu­al sum­mary of the res­ults of their sur­veil­lance activ­it­ies. Swiss­med­ic may de­term­ine both the con­tent of the sum­mary and the form in which it is made avail­able.

4 In case of an ac­tu­al ne­ces­sity for the pro­tec­tion of pub­lic health, Swiss­med­ic shall de­cree the meas­ures un­der Art­icle 66 TPA in a gen­er­al rul­ing.

115 See foot­note to Art. 4 para. 1 let. f.

116 Amended by An­nex 5 No 1 of the O of 4 May 2022 on In Vitro Dia­gnost­ic Med­ic­al Devices, in force since 26 May 2022 (AS 2022 291).

Diese Seite ist durch reCAPTCHA geschützt und die Google Datenschutzrichtlinie und Nutzungsbedingungen gelten.

Feedback
Laden